Strong Financial Performance
Jubilant Pharmova reported a 14 percent year-on-year revenue increase to Rs 8,280 crore for the financial year 2025-26, fueled by significant expansion in its CDMO Sterile Injectables, Allergy Immunotherapy, and Generics divisions. The company announced an 8 percent rise in EBITDA to Rs 1,326 crore and a 7 percent increase in normalized profit after tax to Rs 442 crore, prompting the board to propose a dividend of Rs 5 per equity share.
The Rise of Sterile Injectables
The company’s CDMO Sterile Injectables segment emerged as the primary growth engine, recording a 38 percent revenue jump to Rs 1,755 crore. This growth was largely attributed to the successful operationalization of the new Line 3 facility in Spokane, Washington. The Spokane facility alone saw revenue climb 48 percent to Rs 1,714 crore, with EBITDA margins expanding by 190 basis points to 27 percent.
Strategic Market Positioning
Jubilant Pharmova is capitalizing on shifting global supply chain dynamics, specifically the rising demand for US-based pharmaceutical manufacturing following recent US government tariff implementations. The company has already onboarded one of the world’s largest oncology products for the Line 3 facility, with commercial production slated for late FY27 pending regulatory clearance. This strategic move aligns with a broader effort to secure long-term contracts for high-quality domestic production.
Segmental Performance and Challenges
While the CDMO sector thrived, the company saw varied results across other units. The Generics business reported a significant 250 percent surge in EBITDA to Rs 83 crore, reflecting improved operational efficiency. Conversely, the Radiopharmaceuticals division, which generated Rs 1,178 crore in revenue, faced headwinds due to lower production of SPECT products at the Montreal facility following FDA observations. Management expects these operations to normalize by the second half of FY27 as remediation efforts conclude.
Diversification and Industry Partnerships
To bolster its long-term capabilities, Jubilant Pharmova has entered a strategic partnership with French pharmaceutical firm Pierre Fabre. This collaboration focuses on expanding the company’s footprint in biologics and antibody-drug conjugates within the European market. Additionally, the company completed the consolidation of its API business into Jubilant Biosys Limited, aiming to create a unified platform for end-to-end CRDMO services.
Future Outlook
Investors should monitor the upcoming restart of the Montreal facility and the regulatory progress of the Spokane Line 3 production schedule. As the industry continues to prioritize domestic manufacturing resilience, Jubilant Pharmova’s ability to navigate regulatory hurdles and scale its high-margin injectable capacity will likely determine its momentum through FY27.
